6,040 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Purchased by Legato Capital Management LLC

Legato Capital Management LLC purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 4th quarter, HoldingsChannel reports. The firm purchased 6,040 shares of the specialty pharmaceutical company’s stock, valued at approximately $334,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ANIP. KBC Group NV grew its position in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the period. HighTower Advisors LLC purchased a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $222,000. China Universal Asset Management Co. Ltd. boosted its position in shares of ANI Pharmaceuticals by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after buying an additional 1,582 shares during the period. Finally, James Investment Research Inc. purchased a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $243,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several recent analyst reports. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $77.71.

Insider Buying and Selling

In related news, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,381 shares of company stock valued at $2,441,556 over the last 90 days. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $58.92 on Friday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -107.13 and a beta of 0.74. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a 50 day moving average of $56.96 and a 200 day moving average of $58.36.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.